Trial reportCirculation2015
Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Trial report in Circulation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00094302 (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist), which is not on this map. Cited by 219 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)
Who cites it
219 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients.Heart failure reviews · 2023Pooled it
- Detection of myocardial dysfunction using global longitudinal strain with speckle-tracking echocardiography in patients with vs without rheumatoid arthritis: a systematic review and meta-analysis.Journal of echocardiography · 2023Pooled it
- Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.The Cochrane database of systematic reviews · 2021Pooled it
- Comparison of left ventricular longitudinal systolic function parameters in the prediction of adverse outcome in heart failure with preserved ejection fraction.ESC heart failure · 2021Pooled it
- Pooled it
- Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.The Cochrane database of systematic reviews · 2018Pooled it
- Pharmacological treatments for heart failure with preserved ejection fraction-a systematic review and indirect comparison.Heart failure reviews · 2018Pooled it
- Type 2 diabetes in heart failure with preserved and mildly reduced ejection fraction: insights from the REDUCE-LAP-HF II trial.ESC heart failure · 2026Trial
- The effect of increased plasma potassium on myocardial function; a randomized POTCAST substudy.The international journal of cardiovascular imaging · 2023Trial
- Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial.BMC gastroenterology · 2023Trial
- Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone.Journal of the American Heart Association · 2022Trial
- The effect of spironolactone on diastolic function in haemodialysis patients.The international journal of cardiovascular imaging · 2021Trial
- Associations of Left Ventricular Structure and Function With Blood Pressure in Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.Journal of the American Heart Association · 2020Trial
- Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.Journal of the American College of Cardiology · 2019Trial
- The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.European heart journal · 2019Trial
- Eplerenone in patients with myocardial infarction and "mid-range" ejection fraction: An analysis from the EPHESUS trial.Clinical cardiology · 2019Trial
- Stage I hypertension is associated with impaired systolic function by strain imaging compared with prehypertension: A report from the prever study.Journal of clinical hypertension (Greenwich, Conn.) · 2019Trial
- Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.JACC. Heart failure · 2018Trial
- Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.European journal of heart failure · 2017Trial
- Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.European journal of heart failure · 2017Trial
159 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
backgroundImpairment in left ventricular systolic function has been described in heart failure (HF) with preserved ejection fraction (HFpEF), but its prognostic relevance is not known. We determined whether left ventricular longitudinal strain (LS) is predictive of cardiovascular outcomes in HFpEF beyond clinical and conventional echocardiographic measures. METHODS AND
resultsLS was assessed by 2-dimensional speckle-tracking echocardiography at baseline in 447 patients with HFpEF enrolled in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. At a median follow-up of 2.6 years (interquartile range, 1.5-3.9 years), 115 patients experienced the primary composite outcome of cardiovascular death, HF hospitalization, or aborted cardiac arrest. Impaired LS, defined as an absolute LS <15.8%, was present in 52% of patients and was predictive of the composite outcome (adjusted hazard ratio, 2.14; 95% confidence interval, 1.26-3.66; P=0.005), cardiovascular death alone (adjusted hazard ratio, 3.20; 95% confidence interval, 1.44-7.12; P=0.004), and HF hospitalization alone (adjusted hazard ratio, 2.23; 95% confidence interval, 1.16-4.28; P=0.016) after adjustment for clinical and conventional echocardiographic variables. LS was the strongest echocardiographic predictor of the composite outcome. Exploratory analysis in a subset of 131 patients with follow-up LS assessed after 12 to 18 months demonstrated a trend toward improvement in LS associated with spironolactone in patients enrolled in the Americas but not in Russia or Georgia.
conclusionsImpaired left ventricular systolic function is a powerful predictor of HF hospitalization, cardiovascular death, or aborted cardiac arrest in HFpEF independent of clinical predictors. Impaired LS represents a novel imaging biomarker to identify patients with HFpEF at particularly high risk for cardiovascular morbidity and mortality. CLINICAL
trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.